Clindamycin therapy for chlamydia trachomatis in women

Article Abstract:

Chlamydia trachomatis is the most common sexually transmitted bacterial infection in the US, affecting both men and women. Tetracycline antibiotic therapy is currently the treatment of choice. Pregnant or allergic patients can take erythromycin. Alternative therapies would be helpful for patients intolerant or allergic to certain drugs. Clindamycin has shown promise in eradicating chlamydia in laboratory studies. A group of 246 out of 4,013 sexually active women (6.1 percent) tested positive for chlamydia. Most of the infections were found in the 16- to 25-year-old age group (81.7 percent). Women younger than 16 or older than 35 accounted for 2.4 percent of the infections. Symptoms such as vaginal discharge, swelling of the cervix and pelvic pain were absent in 159 patients (65 percent) with chlamydia. A combined infection with both chlamydia and gonorrhea was present in 26 patients (41 percent). Both erythromycin and clindamycin were effective in eradicating the infection. Of the 56 patients given clindamycin therapy, 48 (85.7 percent) completed the entire course of therapy. This compared with the 25 out of 57 (43.9 percent) of the women taking erythromycin. Side effects included nausea, vomiting, abdominal pain, rash (one patient) and ulcers in the esophagus (one patient). Side effects were responsible for failure to continue therapy in 22 out of 57 (38.6 percent) of the women taking erythromycin, compared with four out of 56 (7.1 percent) in the group receiving clindamycin. Although all patients were cured of chlamydia, patients taking erythromycin experienced more side effects, which caused them to discontinue therapy. (Consumer Summary produced by Reliance Medical Information, Inc.)

Evaluation, Erythromycin, Chlamydia infections, Clindamycin

---

Survival and cell acquisition rates after preimplantation embryo biopsy: use of two mechanical techniques and two mouse strains

Article Abstract:

Modern fertilization technology allows embryos to be created in the laboratory and transferred back to the uterus for implantation. A new technique removes one cell, a blastomere, from the first cells of the fertilized egg, for the diagnosis of genetic diseases. The survival of the embryo after a single cell biopsy depends on the number of cells present at the time of biopsy, the number of cells removed and the technique of removal. A single cell can be removed during embryo biopsy by displacement or aspiration of the embryo. Biopsies were performed on four- and eight-cell mouse embryos using both techniques. The survival and development of the embryos after embryo biopsy were evaluated. Both displacement and aspiration techniques offered similar embryo survival rates. One blastomere can be removed from a four-cell embryo and up to three cells can be removed from a eight-cell embryo without disturbing normal development. When the embryos were transferred for continued development, live mice were born. Since the cells of an eight-cell blastomere are smaller than the cells of the four-cell embryo, removal of one cell is technically easier. Biopsy of mouse embryos before implantation did not alter embryo development. (Consumer Summary produced by Reliance Medical Information, Inc.)

Research, Methods, Human embryo, Fertilization in vitro, Human, Human fertilization in vitro, Embryo transplantation, Reproductive technology

---

Platelet-activating factor treatment of human spermatozoa enhances fertilization potential

Article Abstract:

Treatment with platelet-activating factor (PAF) may increase the fertilization capability of human sperm. PAF is a biological mediator that may be involved in different reproductive processes. Among 23 samples of human sperm, 13 were from patients with 20 million motile sperm or more per milliliter (ml) and 10 were from patients with less than 20 million motile sperm per ml. Treatment with PAF increased the percent penetrations of hamster eggs and the penetration index of the samples from both groups of men. The increase in percent penetrations and the penetration index after treatment with PAF was the same for the samples from both groups of men regardless of the number of motile sperm.

Health aspects, Physiological aspects, Spermatozoa, Infertility, Male, Sperm, Male infertility, Platelet activating factor

Similar abstracts:

• Abstracts: Routine screening for genital chlamydia trachomatis in adolescent females. Acceptability of genital herpes immunization: the role of health beliefs and health behaviors
• Abstracts: Malathion for head lice. Malathion for treatment of head lice. Drugs for head lice
• Abstracts: Adjuvant systemic therapy. Progress in the treatment of early breast cancer. The breast biopsy
• Abstracts: Advances in drug therapy for inflammatory bowel disease. 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity
• Abstracts: Dietary outcome in obese patients treated with a gastroplasty program. Impaired glucose-induced thermogenesis and arterial norepinephrine response persist after weight reduction in obese humans

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.